The testing of a promising coronavirus vaccine innovation, developed by AstraZeneca and the University of Oxford, has been put on hold after one of the testees developed health issues. AstraZeneca believes it’s a unique case and the affected person will recover. This is the vaccine of which the Hungarian government reserved 5 million doses.
It was not clear in the first weeks of August exactly with which vaccine-developer the government had signed an agreement. Gyula Poór, from the Hungarian Science Academy (MTA) pointed out that it was for the vaccine developed at the University of Oxford.
One of the spokesmen of the British-Swedish company said in a statement that the “standard review process triggered a pause to vaccination to allow review of safety data,” statnews.com reports.
The New York Times has written that the illness is transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. AstraZeneca is examining if the issue is due to the vaccine or not.
Featured image by Tamás Kovács/MTI
